Hypogammaglobulinemia

Younger Generations: Key Drivers of the Global Blood Plasma Market in 2023 - Insights on Immunoglobulins, Coagulation Factors, and Albumin-derived Therapies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 15, 2023
Health, Other Health, Prevalence, Antibody, Hospital, Infection, DSM-IV codes, Ageing, Factor IX, Haemophilia, Multiple sclerosis, Plasma, Patient, Developed country, Application, VIII, Blood, Cancer, Conditional sentence, Growth, Immunodeficiency, Injury, Blood product, Hypogammaglobulinemia

By Type: The report splits the global blood plasma market into four different types: Immunoglobulin, Albumin, Coagulation Factors and Others.

Key Points: 
  • By Type: The report splits the global blood plasma market into four different types: Immunoglobulin, Albumin, Coagulation Factors and Others.
  • Immunoglobulin products are derived from blood plasma and are used to treat various medical conditions, including immune deficiencies, autoimmune diseases, and certain infections.
  • By Application: The global blood plasma market can be divided into four segments on the basis of application: Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia and Other.
  • By End User: The report divides the global blood plasma market into three end users: Hospitals, Clinics and Others.

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

Retrieved on: 
Thursday, August 10, 2023
Addition, Christophe, Maintenance, ANC, Priority review, Therapy, SG, European Hematology Association, Line, Conference call, Federation of Clinical Immunology Societies, Neutropenia, PIPE, Disclosure, Clinical trial, CIS, Research, Cash, Doctor of Philosophy, ID, Research and development, State Administrative Expenses, Russell, MD, Physician, Patient, WHIM syndrome, Patent, Immune system, Annual Meetings of the International Monetary Fund and the World Bank Group, EHA, Growth, Wart, G-CSF, R, Rare, Restricted, Conference, Safety, Pharmaceutical industry, Cryptocurrency, Bank, Infection, Hypogammaglobulinemia

Additional data from this ongoing Phase 2 trial are expected to be shared in the fourth quarter of 2023.

Key Points: 
  • Additional data from this ongoing Phase 2 trial are expected to be shared in the fourth quarter of 2023.
  • X4 is planning to initiate a Phase 3 clinical trial evaluating mavorixafor in certain chronic neutropenic disorders in the first half of 2024.
  • X4 will host a conference call and webcast today at 8:30 am ET to discuss these financial results and business highlights.
  • The live webcast and slide presentation can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .

Octapharma Puts a Spotlight on the Infection Burden in Patients With Chronic Lymphocytic Leukaemia (CLL) at the European Hematology Association (EHA) Hybrid Congress 2023

Retrieved on: 
Wednesday, June 7, 2023
Oncology, Health, Other Science, Research, Pharmaceutical, Science, CLL, Infection, Immunodeficiency, University, Victorian Comprehensive Cancer Centre, University of Padua, COVID-19, Clinical trial, Risk, SID, Congress, Death, Medical director, Patient, Guideline, Rigshospitalet, Immunoglobulin G, Glossary of education terms (G–L), Disease, Hypogammaglobulinemia, Safety, Pharmaceutical industry, Medicine, Octapharma

Secondary immunodeficiency (SID) is a common complication in patients with haematological malignancies such as CLL.

Key Points: 
  • Secondary immunodeficiency (SID) is a common complication in patients with haematological malignancies such as CLL.
  • Finally, Professor Livio Trentin, University of Padua, Italy, will speak about his experience using subcutaneous immunoglobulin therapy for infection prophylaxis in patients with CLL.
  • Stephan Stilgenbauer, Professor of Medicine and Medical Director of the Comprehensive Cancer Centre in Ulm, Germany, will chair the session.
  • The results of this analysis on 3,846 SID patients will be displayed and commented during the poster session of the Congress on June 9, 2023:

X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 4, 2023
CIS, Doctor of Philosophy, Associate, Icahn School of Medicine at Mount Sinai, X4, MD, WHIM syndrome, Patient, Translational research, Cell, Research and development, R, University, University of Massachusetts, Therapy, WHIM, Host, Wart, Immunology, Hospital, Rare, Pediatric Blood & Cancer, Safety, Abstract, Conference call, Rheumatology, Mount Sinai, ID, Immune system, Duke University School of Medicine, Federation of Clinical Immunology Societies, Annual Review of Cancer Biology, Restricted, ANC, SG, Clinical trial, Harvard Medical School, State Administrative Expenses, Annual general meeting, Upcoming, Pharmaceutical industry, Medical imaging, Dentistry, Management, Myelokathexis, Pediatrics, Conference, Hypogammaglobulinemia, Infection, Medicine

BOSTON, May 04, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2023 and highlighted key upcoming expected milestones.

Key Points: 
  • “This is an exciting time at X4 as we look forward to delivering on several expected major milestones throughout the rest of 2023,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • Cash, Cash Equivalents & Restricted Cash: X4 had $94.4 million in cash, cash equivalents, and restricted cash as of March 31, 2023.
  • X4 will host a conference call and webcast today at 8:30 am ET to discuss these financial results and business highlights.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com .

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

Retrieved on: 
Monday, December 12, 2022
Security (finance), Fatigue, WHIM, Primary immunodeficiency, ASH, Disease, Neutrophil, Neutropenia, Pediatrics, Medication, Research, Blood, COVID-19, Diagnosis, Clinical trial, G-CSF, Trial of the century, Prevalence, FDA, Safety, Bone marrow, Birth, Society, HCPS, Therapy, Wart, Assistant, Quality of life, Hospital, Medicine, University, WHIM syndrome, Immune system, ANC, Patient, Knowledge Organization (journal), Cell, CXCR4, Degenerative disease, Cyclic neutropenia, Calendar, Risk, Pharmaceutical industry, Health insurance, Myelokathexis, Infection, Hypogammaglobulinemia

BOSTON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today provided a summary of its chronic neutropenia-related presentations at this year’s annual meeting of the American Society of Hematology (ASH), taking place December 10-13, 2022 in New Orleans.

Key Points: 
  • Data analyses continue to show that a single dose of oral mavorixafor effected meaningful increases in ANC across all participants, regardless of disease etiology or use of G-CSF.
  • The Phase 1b clinical trial has now been amended and a Phase 2 trial ( NCT04154488 ) is being initiated by X4 to assess the durability, safety, and tolerability of the chronic use of once-daily, oral mavorixafor in a larger chronic neutropenia patient population.
  • Participants were dosed with a single dose of 400 mg oral mavorixafor to assess the magnitude of treatment response.
  • X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

Global Blood Plasma Derivatives Market Report 2022: Rising Prevalence of Hemophilia Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Health, Biotechnology, Hormone, Respiration, Salt, Mineral, Hypogammaglobulinemia, Virus, Antibody, Osmotic pressure, Serum, Thermoregulation, Ageing, Plant, Haemophilia, Infection, Factor IX, Protein, Plasma, Muscle, United Nations, Hepatitis B, FBS, Factor VIII, Haemophilia A, DNA, Hospital, Coagulopathy, Nutrient, Vitamin, Bleeding, Incidence, Blood, Joint, Genetic engineering, Molecular biology, VIII, Application, Coagulation, Hepatitis C, Protease, HIV, Trauma, IX, Blood product, Vaccine

The Global Blood Plasma Derivatives Market size is expected to reach $72.5 billion by 2028, rising at a market growth of 9.3% CAGR during the forecast period.

Key Points: 
  • The Global Blood Plasma Derivatives Market size is expected to reach $72.5 billion by 2028, rising at a market growth of 9.3% CAGR during the forecast period.
  • Blood plasma derivatives are specific protein concentrates extracted from plasma using a fractionation technique.
  • In addition, blood plasma derivatives aid in boosting nutrition, regulating body temperature and blood coagulation, maintaining osmotic pressure, improving respiration as well as excretion, and balancing acid-base levels.
  • In hospitals, clinics, diagnostic facilities, and blood transfusion centers, blood plasma derivatives are widely preserved.

The European CAR-T Cell Therapy Industry is Expected to Reach $1.9 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 27, 2022
Oncology, Health, Hospitals, Genetics, Pharmaceutical, Biotechnology, Growth, Marketing, Kite Pharma, COVID-19, Patient, CAR, Awareness, Research, European Medicines Agency, Immunodeficiency, Drug development, Hypogammaglobulinemia, Cancer, Health, Cytopenia, Vaccine, Pharmaceutical industry

The CAR-T Cell Therapy market is a conceptual examination of all commercial activities related to CAR-T Cell Therapy, either directly or indirectly.

Key Points: 
  • The CAR-T Cell Therapy market is a conceptual examination of all commercial activities related to CAR-T Cell Therapy, either directly or indirectly.
  • As a result, a new investor can learn about CAR-T Cell Therapy firms, their important products, their basic strategy, key CAR-T Cell Therapy market trends, and more.
  • Increase in awareness about the new approach to treat cancer leads to increase in demand for the CAR-T cell therapy products.
  • Some potential challenges associated with CAR T development is likely to hamper the growth of the Europe CAR-T Cell Therapy market.

Intravenous Immunoglobulin Global Market Report 2022: Rising Prevalence of Immunodeficiency Diseases Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 18, 2022
Infectious Diseases, Pharmaceutical, Health, Immunodeficiency, National Institute, Immunoglobulin D, Industry, European Federation of Pharmaceutical Industries and Associations, Guillain–Barré syndrome, EFPIA, Prevalence, Hypogammaglobulinemia, Pharmacy, Infection, Immunoglobulin G, Immunoglobulin M, India Brand Equity Foundation, Chiapas, CAGR, Patient, Hospital, Purpura, Consumer, NIAID, Investment, Federalisation of the European Union, Myasthenia gravis, Immunoglobulin E, Immunoglobulin therapy, National Institute of Allergy and Infectious Diseases, Radiation therapy, Myopathy, Immunoglobulin A, Vaccination, Multifocal motor neuropathy, FDA, Chronic inflammatory demyelinating polyneuropathy, Vaccine, Fine chemical

Rising prevalence of immunodeficiency diseases and the increasing geriatric population fuel the overall market growth.

Key Points: 
  • Rising prevalence of immunodeficiency diseases and the increasing geriatric population fuel the overall market growth.
  • Based on the type, the intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD.
  • Based on application, the intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others.
  • Based on distribution channel, the intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others.

X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia

Retrieved on: 
Wednesday, August 31, 2022
G-CSF, B-cell lymphoma, Partnership, Security (finance), Safety, Cancer, CXCR4, Trial of the century, Lists of diseases, Research, Neutropenia, Medication, Immunodeficiency, WHIM, WHIM syndrome, SEC, U.S. Securities and Exchange Commission, Cyclic neutropenia, GLOBE, WM, Biology, Immune system, Therapy, Risk, Clinical trial, Private Securities Litigation Reform Act, Q&A, Forward-looking statement, Patient, Pharmaceutical industry, Infection, Hypogammaglobulinemia, Myelokathexis

Members of X4 Pharmaceuticals management team will present clinical data on 25 patients from this fully enrolled trial and discuss mavorixafors potential to treat broader chronic neutropenia populations beyond its lead indication in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome.

Key Points: 
  • Members of X4 Pharmaceuticals management team will present clinical data on 25 patients from this fully enrolled trial and discuss mavorixafors potential to treat broader chronic neutropenia populations beyond its lead indication in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome.
  • The clinical trial ( NCT04154488 ) is a proof-of-concept Phase 1b open-label, multicenter study designed to assess the safety and tolerability of daily, oral mavorixafor with or without G-CSF, in participants with chronic neutropenic disorders including severe congenital, idiopathic, or cyclic neutropenia.
  • Participants were dosed with a single dose of oral mavorixafor to assess the magnitude of treatment response.
  • X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with diseases of the immune system.

X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 4, 2022
Private Securities Litigation Reform Act, ANC, Research and development, Security (finance), COVID-19, WM, MYD88, Clinical trial, CXCR4, Hercules, Wart, R rating, General officer, Patient, Biology, EHA, Immunodeficiency, Safety, U.S. Securities and Exchange Commission, BTK, Conference call, Adult, B-cell lymphoma, Research, European Hematology Association, SG, Forward-looking statement, Cancer, Therapy, Achievement, PIPE, GLOBE, R, Conference, ID, WHIM syndrome, EDT, Medication, State Administrative Expenses, Immune system, Cyclic neutropenia, Risk, Partnership, SEC, Pharmaceutical industry, Lithium, Hypogammaglobulinemia, Infection

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small-molecule therapeutics to benefit people with diseases of the immune system, today reported financial results for the second quarter ended June 30, 2022. In addition, the company highlighted important upcoming milestones related to its lead clinical candidate, mavorixafor, including the presentation of data from its ongoing Phase 1b clinical trial in chronic neutropenic disorders and from the global, pivotal Phase 3 clinical trial of mavorixafor in WHIM (Warts, Hypogammaglobulinemia, Infections, & Myelokathexis) syndrome. The company also provided an update on its clinical oncology program following its recent strategic announcement prioritizing its use of resources to advance mavorixafor solely in chronic neutropenic disorders.

Key Points: 
  • R&D expenses include $0.7 million and $0.8 million of certain non-cash expenses for the second quarter of 2022 and 2021, respectively.
  • SG&A expenses include $0.8 million and $1.0 million of certain non-cash expenses for the second quarter of 2022 and 2021, respectively.
  • Net losses include $1.5 million and $1.8 million of certain non-cash expenses for the second quarter of 2022 and 2021, respectively.
  • X4 will host a conference call and webcast today at 8:30 am EDT to discuss financial results and business highlights.